France’s Sanofi on Monday agreed to buy California-headquartered biotechnology firm Synthorx in a cash deal worth about $2.5 billion as it steps up a push in the lucrative field of cancer drugs under its new chief executive.
France’s Sanofi to buy biotech firm Synthorx for $2.5 billion
Leave a Reply